Strategies to Improve the Lipophilicity of Hydrophilic Macromolecular Drugs
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202503721 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Sera Lindner und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology, University of Innsbruck, Institute of Pharmacy, Center for Chemistry and Biomedicine, Innsbruck, 6020, Austr…. Hauptthemen laut MEDLINE: Macromolecular Substances, Lipids. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 216 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Macromolecular drugs, including peptides, proteins, oligonucleotides, and polysaccharides, have shown remarkable therapeutic potential due to their high specificity, potency, and low toxicity profiles. However, their clinical translation, particularly for oral administration, remains limited by poor bioavailability arising from poor membrane permeability and enzymatic instability. Enhancing the lipophilicity of these molecules is a critical strategy to overcome these challenges, improving their membrane permeability, stability, and pharmacokinetic properties. This review discusses current strategies to improve the lipophilicity of macromolecular drugs, focusing on covalent and non‐covalent lipidation. Covalent lipidation, which involves the conjugation of lipids such as fatty acids or steroids, provides stable chemical modifications that have led to several commercially successful products. However, it also presents regulatory complexities due to the formation of new active pharmaceutical ingredients. In contrast, non‐covalent lipidation methods, such as hydrophobic ion pairing and reverse micelle formation, offer reversible alternatives that preserve the native structure of the drug, simplify regulatory procedures, and allow flexible tuning of delivery properties. Notably, reverse micelle systems demonstrate superior performance compared to hydrophobic ion pairs, particularly in enhancing the lipophilicity of larger, more complex macromolecules. While lipidation strategies have significantly advanced the field, substantial challenges remain, especially in achieving consistent bioavailability and translating preclinical success into clinical efficacy. Future progress will require innovative ideas and the integration of emerging technologies to fully unlock the potential of lipidated macromolecular therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Technology, University of Innsbruck, Institute of Pharmacy, Center for Chemistry and Biomedicine, Innsbruck, 6020, Austria.
- Center for Sustainable Materials, School of Materials Science and Engineering, Nanyang Technological University, Singapore, 639789, Singapore.
- Thiomatrix Forschungs- und Beratungs GmbH, Trientlgasse 65, Innsbruck, 6020, Austria.
- Department of Pharmaceutical Science, Trakia University-Stara Zagora, Stara Zagora, 6000, Bulgaria.
ORCID-Profile: Andreas Bernkop-Schnürch
Zitieren
APA
Lindner, S., Keim, S., Haddadzadegan, S., Fernandez Romero, O., Zöller, K., Stern, G., Cesi, I., Kafedjiiski, K., & Bernkop-Schnürch, A. (2026). Strategies to Improve the Lipophilicity of Hydrophilic Macromolecular Drugs. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503721
Vancouver
Lindner S, Keim S, Haddadzadegan S, Fernandez Romero O, Zöller K, Stern G, et al. Strategies to Improve the Lipophilicity of Hydrophilic Macromolecular Drugs. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202503721
BibTeX
@article{Lindner2026,
author = {Lindner, Sera and Keim, Stefan and Haddadzadegan, Soheil and Fernandez Romero, Odile and Zöller, Katrin and Stern, Gabriel and Cesi, Ilaria and Kafedjiiski, Krum and Bernkop-Schnürch, Andreas},
title = {Strategies to Improve the Lipophilicity of Hydrophilic Macromolecular Drugs},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202503721}
}
EUVIMED